2. Search Result
Search Result
Results for "

thromboembolic disorders

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0366A
    Cyproheptadine hydrochloride
    3 Publications Verification

    		 5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
    Cyproheptadine hydrochloride
  • HY-B1622
    Cyproheptadine
    3 Publications Verification

    		 5-HT Receptor Apoptosis Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
    Cyproheptadine
  • HY-15799
    AZD1283

    		P2Y Receptor Cardiovascular Disease
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
    AZD1283
  • HY-14878
    (2R)-Atecegatran

    (2R)-AZD-0837

    		 Thrombin Cardiovascular Disease
    (2R)-Atecegatran ((2R)-AZD-0837; (Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab)) is a thrombin inhibitor. (2R)-Atecegatran can be used in research related to thromboembolic disorders .
    (2R)-Atecegatran
  • HY-10758
    FXa-IN-1

    		Factor Xa Cardiovascular Disease
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .
    FXa-IN-1
  • HY-10273
    Atecegatran metoxil

    AZD0837; Atecegatran fexenetil

    		 Thrombin Cardiovascular Disease
    Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.
    Atecegatran metoxil
  • HY-B1622R
    Cyproheptadine (Standard)

    		5-HT Receptor Apoptosis Cardiovascular Disease Neurological Disease
    Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
    Cyproheptadine (Standard)
  • HY-B0366AR
    Cyproheptadine hydrochloride (Standard)

    		5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine (hydrochloride) (Standard) is the analytical standard of Cyproheptadine (hydrochloride). This product is intended for research and analytical applications. Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
    Cyproheptadine hydrochloride (Standard)
  • HY-10275
    Atecegatran

    AR-H067637

    		 Thrombin Cardiovascular Disease
    Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .
    Atecegatran
  • HY-111755
    Oral antiplatelet agent 1

    		P2Y Receptor Cardiovascular Disease
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
    Oral antiplatelet agent 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: